$20.07
0.05% yesterday
Nasdaq, Dec 24, 07:00 pm CET
ISIN
US64049K1043
Symbol
NGNE

Neoleukin Therapeutics Inc Stock price

$20.07
-0.37 1.81% 1M
+2.87 16.69% 6M
-2.79 12.20% YTD
-2.55 11.27% 1Y
+11.42 132.02% 3Y
-271.13 93.11% 5Y
-233.13 92.07% 10Y
-218.93 91.60% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
-0.01 0.05%
ISIN
US64049K1043
Symbol
NGNE
Industry

Key metrics

Basic
Market capitalization
$310.9m
Enterprise Value
$45.5m
Net debt
positive
Cash
$265.4m
Shares outstanding
14.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.2
Financial Health
Equity Ratio
92.5%
Return on Equity
-24.2%
ROCE
-16.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-42.3m | -
EBIT
$-45.3m | $-105.4m
Net Income
$-40.5m | $-63.3m
Free Cash Flow
$-78.4m
Growth (TTM | estimate)
Revenue
-100.0% | -100.0%
EBITDA
40.8% | -
EBIT
40.8% | -27.8%
Net Income
43.1% | 15.8%
Free Cash Flow
6.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.9
FCF per Share
$-5.3
Short interest
26.4%
Employees
107
Rev per Employee
$10.0k
Show more

Is Neoleukin Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Neoleukin Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Neoleukin Therapeutics Inc forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Neoleukin Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Neoleukin Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 13 13
16% 16%
-
- Research and Development Expense 33 33
60% 60%
-
-42 -42
41% 41%
-
- Depreciation and Amortization 3.05 3.05
41% 41%
-
EBIT (Operating Income) EBIT -45 -45
41% 41%
-
Net Profit -40 -40
43% 43%
-

In millions USD.

Don't miss a Thing! We will send you all news about Neoleukin Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neoleukin Therapeutics Inc Stock News

Neutral
Business Wire
21 days ago
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 4,860 shares of the Company's common s...
Positive
Seeking Alpha
about one month ago
Neurogene has transitioned into a data-driven, registrational-stage company with NGN-401 showing strong safety and efficacy for Rett syndrome. NGNE's disciplined financial management provides a cash runway through Q1 2028, allowing focused investment in its lead asset and minimizing dilution risk. NGN-401's clinical data demonstrate durable, multi-domain functional gains and a favorable safety ...
Neutral
Business Wire
about one month ago
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter 2025 financial results and highlighted recent corporate updates. “We significantly advanced our NGN-401 gene therapy clinical program for Rett syndrome over the past quar...
More Neoleukin Therapeutics Inc News

Company Profile

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.

Head office United States
CEO Rachel McMinn
Employees 107
Founded 2018
Website www.neurogene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today